Shenzhen: procurement of 11 non-Chinese products has been stopped. Haizheng Pfizer, sanders (China), Dongting Pharmaceutical

Recently, Shenzhen issued the notice on publicizing the results of adjustment in Shenzhen area of centralized drug purchase in 4 + 7 cities by Shenzhen City, Guangdong Province in 2019, which adjusted the results of the purchase catalogue of Shenzhen public hospital drug group in 2016 for the non selected drugs with the same common name and the same medication route (oral regular release or injection) as the selected drugs in 4 + 7 cities 。 The adjustment involves 48 drug specifications, 37 of which are adjusted to meet the adjustment requirements and continue to be supplied; 8 of which do not agree to be adjusted as required and will not be supplied any more: including escitalopram of Hunan Dongting Pharmaceutical Co., Ltd., irbesartan of Haizheng Pfizer Pharmaceutical Co., Ltd., rosuvastatin calcium of Xiansheng Dongyuan Pharmaceutical Co., Ltd., losartan potassium of sanders (China), paroxetine of Wansheng Pharmaceutical Co., Ltd., Dazhong, Sichuan Province Montelukast of pharma and Hangzhou MSD pharmaceutical For the other three specifications of drugs, more than three enterprises (including three) have been evaluated for consistency, and their supply has been stopped, including atorvastatin from Sandoz (China), amlodipine from Beijing medihai Pharmaceutical Co., Ltd., and montmorillonite from Hunan qianjinxiangjiang Pharmaceutical Co., Ltd Details are as follows: